Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$7.15 - $10.84 $192,585 - $291,975
-26,935 Reduced 36.04%
47,808 $445,000
Q4 2023

Feb 14, 2024

SELL
$6.28 - $8.81 $840,383 - $1.18 Million
-133,819 Reduced 64.16%
74,743 $630,000
Q3 2023

Nov 14, 2023

SELL
$7.55 - $11.25 $1.97 Million - $2.93 Million
-260,715 Reduced 55.56%
208,562 $1.62 Million
Q2 2023

Aug 14, 2023

BUY
$6.94 - $13.99 $2.79 Million - $5.63 Million
402,280 Added 600.44%
469,277 $5.37 Million
Q1 2023

May 15, 2023

BUY
$6.0 - $10.78 $401,982 - $722,227
66,997 New
66,997 $516,000
Q3 2022

Nov 14, 2022

BUY
$5.57 - $7.47 $1.06 Million - $1.42 Million
189,736 New
189,736 $1.12 Million
Q2 2022

Aug 15, 2022

SELL
$4.82 - $10.09 $1.47 Million - $3.08 Million
-305,445 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$2.75 - $9.44 $375,199 - $1.29 Million
-136,436 Reduced 30.88%
305,445 $2.33 Million
Q4 2021

Feb 14, 2022

BUY
$2.47 - $5.55 $1.04 Million - $2.33 Million
420,029 Added 1922.15%
441,881 $1.2 Million
Q2 2021

Aug 13, 2021

SELL
$3.94 - $5.44 $42,721 - $58,985
-10,843 Reduced 33.16%
21,852 $90,000
Q1 2021

May 17, 2021

BUY
$4.61 - $9.04 $150,723 - $295,562
32,695 New
32,695 $154,000
Q3 2020

Nov 16, 2020

SELL
$10.01 - $13.75 $960,499 - $1.32 Million
-95,954 Closed
0 $0
Q2 2020

Aug 13, 2020

SELL
$8.05 - $14.21 $792,844 - $1.4 Million
-98,490 Reduced 50.65%
95,954 $1.21 Million
Q1 2020

May 15, 2020

BUY
$6.8 - $14.66 $1.32 Million - $2.85 Million
194,444 New
194,444 $1.78 Million
Q4 2019

Feb 14, 2020

SELL
$12.82 - $16.85 $540,247 - $710,075
-42,141 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$16.31 - $28.29 $687,319 - $1.19 Million
42,141 New
42,141 $725,000
Q4 2018

Feb 14, 2019

SELL
$8.59 - $18.05 $504,653 - $1.06 Million
-58,749 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$17.11 - $21.74 $1.01 Million - $1.28 Million
58,749 New
58,749 $1.11 Million

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $207M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.